Table 2 Oncologic and functional outcomes
From: Pilot study comparing the two hemostatic agents in patients undergoing partial nephrectomy
Variable | Total cohort (N = 23) | Floseal® cohort (N = 11) | Arista® cohort (N = 12) | p value |
|---|---|---|---|---|
Histology | 0.34 | |||
Clear cell | 17 (74%) | 9 (82%) | 8 (66%) | |
Papillary | 2 (9%) | 0 (%) | 2 (17%) | |
Chromophone | 1 (4%) | 1 (9%) | 0 (0%) | |
Oncocytoma | 3 (13%) | 1 (9%) | 2 (17%) | |
Pathologic stage | 0.86 | |||
T1a | 14 (70%) | 7 (70%) | 7 (70%) | |
T1b | 6 (30%) | 3 (30%) | 3 (30%) | |
Furhman grade | 0.14 | |||
1 | 8 (40%) | 6 (60%) | 2 (20%) | |
2 | 11 (55%) | 4 (40%) | 7 (70%) | |
3 | 1 (5%) | 0 (0%) | 1 (10%) | |
4 | 0 (0%) | 0 (0%) | 0 (0%) | |
Pos. surgical margin | N.A. | |||
0 (0%) | 0 (0%) | 0 (0%) | ||
Mean post-operative GFR (mL/min/1.73 m2) | 70.9 ± 18.7 | 66.9 ± 21.8 | 74.5 ± 15.4 | 0.34 |
Hospital stay/days | 4.5 ± 0.9 | 4.4 ± 1.2 | 4.5 ± 0.7 | 0.76 |